Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

Video

In Partnership With:

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Yi Lin, MD, PhD, consultant, Division of Hematology, Department of Internal Medicine, consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, assistant professor of medicine and oncology, Mayo Clinic, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Multiple BCMA-directed CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates are demonstrating significant efficacy for patients with multiple myeloma. However, the field is developing non-BCMA–targeted options as well, Lin explains.

Early data with non-BCMA–targeting approaches are showing high rates of early responses in patients, says Lin. With the rapid growth of immunotherapy in multiple myeloma, data will likely emerge in the coming years showing that non-BCMA–directed therapies are good options for patients, concludes Lin.

Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Haeseong Park, MD, MPH
Matthew P. Goetz, MD
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center